<DOC>
	<DOCNO>NCT00004584</DOCNO>
	<brief_summary>The purpose study look safety effectiveness experimental protease inhibitor ( type anti-HIV drug ) call BMS-232632 . Doctors compare anti-HIV drug combination include BMS-232632 drug combination include ritonavir .</brief_summary>
	<brief_title>Safety Effectiveness New Protease Inhibitor , BMS-232632 , HIV-Positive Patients Who Have Received Previous Treatment</brief_title>
	<detailed_description>This three-arm study ; patient randomize receive BMS-232632 two different dos RTV combination SQV two nucleoside analogue 48 week . Randomization stratify baseline phenotypic sensitivity .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load ( level HIV blood ) least 2,000 copies/ml . Have CD4 count least 100 cells/mm3 ( least 75 cells/mm3 patient never AIDSdefining illness ) . Are currently receive antiHIV drug combination include protease inhibitor nonnucleoside reverse transcriptase inhibitor ( NNRTI ) , take drug combination least 24 week . They must respond well treatment first ( viral load decrease ) currently experience increase viral load . Will likely respond well study drug , show result lab test . Are least 18 year old . Agree use effective barrier method birth control ( condom ) . Are available followup least 48 week . Exclusion Criteria Patients eligible study : Have newly diagnose opportunistic ( HIVrelated ) infection require treatment . Have recently become HIV positive . Abuse alcohol drug . Have severe diarrhea within 30 day study entry . Have hemophilia . Have history pancreatitis . Have hepatitis within 30 day study entry . Have peripheral neuropathy ( painful condition affect nervous system ) . Are unable take medication mouth . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>